CCL2 supports human hepatocytes long-term expansion for bioartificial liver therapy to relieve acute liver failure and extrahepatic complications
Year: 2025
Type: article
Abstract: mice following 2-(2-nitro-4-trifluoromethylbenzyol)-1,3- cyclohexanedione (NTBC) withdrawal. Further studies revealed that CCL2-mediated hepatocyte proliferation could yield a sufficient number of highly active and well-functioning hepatocytes, crucial for supporting Bioartificial liver (BAL) therapy in treating acute liver failure (ALF) in a porcine model. Mechanically, BAL therapy effectively suppresses inflammatory responses, promotes liver regeneration, and subsequently protects extrahepatic organs, leading to improved survival rates in ALF porcine models.
DOI: 10.7150/ijbs.115293
Authors: Zibin Zhan, Xuewen Liu, Min Zeng, Zehua Li, Yue Zhang, Xueyan Qiao, Xinming Li, Xianfeng Xia, Kunhao Bai, Fanhong Zeng, Yi Gao, Jun Weng
Institutions: Zhujiang Hospital, Southern Medical University, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Second Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Chinese University of Hong Kong, University of Hong Kong
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,337
OpenAlex ID: W4416016297
FWCI:
Cites:
Cited by:
Related to: